Tag: Immune mediated adverse reactions
The FDA has fully approved Keytruda, a Merck anti-PD-1 medication, for use in a small number of adult and paediatric patients with advanced MSI-H or mismatch repair deficient solid tumours.
The US Food and Drug Administration (FDA) has fully approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of…
Registration Form
This will close in 0 seconds
